.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Citi
Federal Trade Commission
Moodys
McKinsey
Harvard Business School
Express Scripts
Baxter
Queensland Health
Mallinckrodt

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207923

« Back to Dashboard
NDA 207923 describes SEEBRI, which is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the SEEBRI profile page.

The generic ingredient in SEEBRI is glycopyrrolate. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

Summary for NDA: 207923

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 207923

Mechanism of ActionCholinergic Antagonists

Suppliers and Packaging for NDA: 207923

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SEEBRI
glycopyrrolate
POWDER;INHALATION 207923 NDA Novartis Pharmaceuticals Corporation 0078-0662 0078-0662-06 6 CAPSULE in 1 BOX, UNIT-DOSE (0078-0662-06)
SEEBRI
glycopyrrolate
POWDER;INHALATION 207923 NDA Novartis Pharmaceuticals Corporation 0078-0662 0078-0662-19 60 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0662-19) > 1 CAPSULE in 1 BLISTER PACK (0078-0662-61)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength15.6MCG/INH
Approval Date:Oct 29, 2015TE:RLD:Yes
Patent:7,736,670Patent Expiration:Jun 27, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:8,048,451Patent Expiration:Jun 27, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:8,182,838Patent Expiration:Oct 20, 2028Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 207923

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 20156,521,260► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Dow
Johnson and Johnson
Boehringer Ingelheim
Accenture
Merck
McKesson
Harvard Business School
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot